An audit of infusion-related reactions with biosimilar rituximab in London

An important question regarding the use of biosimilar rituximab is whether rapid infusion rates are safe, as they are for the original. Speaking from the British Oncology Pharmacy Association (BOPA) 2... Author: VJHemOnc Added: 01/03/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts